(Q38825446)

English

Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry

scientific article published on 21 April 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

hospitalization

1 reference

based on heuristic

inferred from title

Gian Paolo Fadini

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

7

object named as

Angelo Avogaro

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Saula Vigili de Kreutzenberg

5

object named as

Saula Vigili de Kreutzenberg

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Stefania Saragoni

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Pierluigi Russo

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Luca Degli Esposti

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Mario Melazzini

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

OsMed Health DB Network

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

21 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1416-1424

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

DPP-4 inhibition has beneficial effects on the heart after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Databas

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Attending the diabetes center is associated with increased 5-year survival probability of diabetic patients: the Verona Diabetes Study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Identifiers

10.1111/DOM.12979

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38825446&oldid=2199585525"